DIANTHUS THERAPEUTICS INC
DNTHNASDAQ🏆 #1329 by market capUS Equity
$82.36▼ $0.01 (−0.01%)
Latest quoteTrack DNTH
Get earnings, price moves & breaking news on Telegram
24h▼ 0.0%
7d▲ 4.6%
14d▲ 10.6%
30d▼ 5.6%
ytd▲ 99.9%
1y▲ 143.7%
🏦Market Cap
$4.61B
Small Cap
📈Revenue Growth (YoY)
-60.8%
Declining
📊Gross Margin
—
💵FCF Margin
—
⚖️P/S Ratio
2328.6x
Expensive
Otter Score
—
Insufficient data
Trading Snapshot
- Day Range
- $82.07 – $83.45
- 52-Week Range
- $32.28 – $117.88
- Volume (shares)
- 12,162
- Avg Volume (shares)
- —
- Shares Outstanding
- 55.9M
- Next Earnings
- —
Fundamentals Snapshot
- Annual Revenue
- $2M
- Last Q Revenue
- $761,000
- P/E Ratio
- —
- P/S Ratio
- 2328.6x
- EPS (TTM)
- $-4.15
- Dividend Yield
- —
- Dilution (1yr)
- +7.9%
DIANTHUS THERAPEUTICS INC
DNTHFinancial Trends
RevenueThe total money the company brought in from sales, before subtracting any costs.
$2M▼ −67.3% YoY
Gross MarginOf every $1 of sales, how much is left after the direct cost of making the product/service. Higher = more efficient.
100.0%▲ +0.0% YoY
Operating IncomeProfit from the core business after operating costs, but before interest and taxes. Negative means the core business isn’t profitable yet.
−$178M▲ +74.7% YoY
Free Cash FlowCash left over after running the business and paying for equipment/capex. Negative means the company is burning cash.
−$129M▲ +65.1% YoY
Shares OutstandingHow many shares exist. Rising means the company is issuing more shares, which dilutes (shrinks) each existing owner’s slice.
37.8M▲ +7.9% YoY
Net CashCash minus total debt. Positive = more cash than debt (financially strong); negative = more debt than cash (net debt).
$50M▲ +$28M YoY
StockOtter · stockotter.spaceAbout DIANTHUS THERAPEUTICS INC
Dianthus Therapeutics, Inc., a clinical-stage biotechnology company, engages in the development of therapies for patients with severe autoimmune diseases. Its lead clinical-stage candidate, claseprubart, a monoclonal antibody engineered with extended half-life, improved potency, and high selectivity for only the active C1s complement protein; and DNTH212, a bifunctional fusion protein that targets plasmacytoid dendritic cell (pDC) BDCA2 to reduce Type 1 interferon production, while simultaneously inhibiting BAFF/APRIL to suppress B cell function. Dianthus Therapeutics, Inc. was founded in 2019 and is headquartered in New York, New York.
🦦
Otter Score Breakdown
How it's scoredFive components, each rated 1–5★ and equally weighted (20%), averaged to a 0–100 score:💎 Quality — gross margin🚀 Growth — revenue YoY⚖️ Valuation — P/S ratio⚡ Momentum — 30-day price change💧 Dilution — 1-yr share issuance (buybacks score higher)Insufficient data for all five components.
🚀Growth★★★★★
⚖️Valuation★★★★★
⚡Momentum★★★★★
💧Dilution★★★★★
Overall Score
Insufficient data
—/100
Analyst data unavailable.
Latest News & Updates
News unavailable.